Physician profile
Richard Levine
NPI 1497758502
$954.26
in general payments reported to CMS, 2019-2025
10 companies · $16.62 in 2025
The $16.62 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $177 · 2021: $480 · 2025: $16.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipla USA INC. | $295.50 | 2021 | |
| Allergan, INC. | $192.77 | 2019-2021 | |
| Viiv Healthcare Company | $161.02 | 2019-2021 | |
| Insmed, INC. | $95.59 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $72.53 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $55.36 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $33.00 | 2020 | |
| Medline Industries LP | $16.62 | 2025 | |
| Pfizer INC. | $16.13 | 2019 | |
| Nabriva Therapeutics, Plc | $15.74 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.